Numerous structural genetic abnormalities observed in acute myeloid leukemia (AML) illustrate the heterogeneity of this disease, which likely has contributed to difficulty in identifying susceptibility alleles for AML. We previously reported that carriers of the glutamine-encoding allele at codon 751 of the xeroderma pigmentosum group D (XPD) DNA repair gene were significantly more likely to have a karyotype associated with a less favorable prognosis, and hypothesized that this observation was driven by an association between the codon 751 variant and risk of developing AML with specific structural abnormalities. Using a case series of 927 patients with AML, we show here that the XPD codon 751 glutamine-encoding variant significantly associates with risk of developing AML with a chromosome 5q deletion (odds ratio [OR] 2.09; 95% confidence interval [CI] 1.14-3.81; n = 69; P = .02) or a chromosome 7q deletion (OR 2.27; 95% CI 1.09-4.71; n = 47; P = .03), but not with any other commonly recurring cytogenetic lesion.

Acute myeloid leukemia (AML) can be characterized by the somatic acquisition of gross genomic abnormalities, including translocations, inversions, deletions, and chromosomal trisomy and monosomy. The structural diversity of these lesions suggests that the mechanisms underlying their generation are likely to be varied. Given this, we hypothesized that whereas some risk factors for AML will be common to all subtypes and independent of karyotype, other risk factors, including some genetic susceptibility alleles, will be unique to subgroups with defined molecular lesions. We have previously shown that carriers of the xeroderma pigmentosum group D (XPD) codon 751 glutamine-encoding polymorphism were more likely to have a karyotype associated with a less favorable prognosis (n = 308 cases, test for trend P = .008).1 XPD encodes a protein with DNA helicase activity that mediates the DNA unwinding required for basal transcription and nucleotide excision DNA repair (NER). Given its role in DNA repair we hypothesized that polymorphic XPD predisposes to the formation of 1 or more specific chromosomal lesions, and that this might explain the observed association with a less-than-favorable karyotype. In order to test this, we determined XPD codon 751 polymorphism status in a series of 927 AML cases, enriched for those with a complex karyotype and chromosome 5 and/or 7 deletions.

Patients and samples

We examined XPD codon 751 status in 927 individuals diagnosed with AML. These included 343 patients recruited as part of a large population-based case-control study of acute leukemia conducted in the United Kingdom,2  558 patients enrolled in the United Kingdom Medical Research Council AML trials (nos. 10, 11, and 12) between May 1988 and May 2002,3-6  and 66 patients recruited as part of a therapy-related leukemia study conducted in the United Kingdom1,7,8  (Table 1). Ethical approval was obtained for these studies. Informed consent was provided according to the Declaration of Helsinki. This study has been registered with the University of York, Department of Biology Ethics Committee.

Table 1

Description of study subjects by sex, age, and cytogenetic abnormality

Medical Research Council (MRC) trials
Leukaemia Research (LRF) studies
Total*
AML 10AML 11AML 12AMLTherapy AML
Total, no. (%) 30 321 207 343 66 927 
Sex, no. (%) 
    Male 16 (53.3) 182 (56.7) 120 (58.0) 188 (54.8) 28 (42.4) 512 (55.2) 
    Female 14 (46.7) 139 (43.3) 87 (42.0) 155 (45.2) 38 (57.6) 415 (44.8) 
Age 
    Mean, y (standard deviation) 41.4 (11.6) 66.8 (5.5) 41.0 (12.1) 47.3 (14.5) 55.1 (13.1) 52.4 (15.6) 
    16 to 39 y, no. (%) 9 (30.0) 88 (42.5) 108 (31.5) 11 (16.7) 213 (23.0) 
    40 to 59 y, no. (%) 21 (70.0) 36 (11.2) 117 (56.5) 150 (43.7) 27 (40.9) 338 (36.5) 
    60 y or older, no. (%) 285 (88.8) 2 (1.0) 85 (24.8) 28 (42.4) 376 (40.6) 
Cytogenetic abnormalities, no. (%) 
    Normal 140 (26.9) 73 (23.2) 146 (30.4) 20 (16.4) 363 (25.1) 
    Monosomy 
        −5 3 (4.0) 20 (3.9) 10 (3.2) 7 (1.5) 4 (3.3) 42 (2.9) 
        −7 9 (11.8) 35 (6.7) 12 (3.8) 15 (3.1) 12 (9.8) 78 (5.4) 
    Trisomy 
        +8 3 (4.0) 36 (6.9) 17 (5.4) 38 (7.9) 10 (8.2) 100 (6.9) 
        +21 2 (2.6) 6 (1.2) 5 (1.6) 9 (1.9) 1 (0.8) 22 (1.5) 
        +22 1 (1.3) 4 (0.8) 4 (1.3) 3 (0.6) 1 (0.8) 13 (0.9) 
    Translocation 
        t(15;17) 1 (1.3) 11 (2.1) 33 (10.5) 42 (8.3) 8 (6.6) 90 (6.2) 
        t(8;21) 1 (1.3) 6 (1.2) 16 (5.1) 24 (5.0) 47 (3.3) 
    Deletion 
        del(5q) 10 (13.2) 39 (7.5) 11 (3.5) 7 (1.5) 4 (3.3) 69 (4.8) 
        del(7q) 6 (7.9) 17 (3.3) 12 (3.8) 15 (3.1) 4 (3.3) 47 (3.3) 
        del(9q) 1 (1.3) 8 (1.5) 7 (2.2) 6 (1.3) 1 (0.8) 22 (1.5) 
    Other 
        3q 10 (1.9) 11 (3.5) 9 (1.9) 5 (4.1) 39 (2.7) 
        11q23 7 (9.2) 8 (1.5) 9 (2.9) 14 (2.9) 8 (6.6) 41 (2.8) 
        Inversion(16) 1 (1.3) 4 (0.8) 7 (2.2) 14 (2.9) 1 (0.8) 26 (1.8) 
        Complex 8 (10.5) 49 (9.4) 25 (7.9) 24 (5.0) 12 (9.8) 112 (7.8) 
        Any other abnormality 18 (23.7) 126 (24.3) 63 (20.0) 113 (23.5) 31 (25.4) 333 (23.0) 
Medical Research Council (MRC) trials
Leukaemia Research (LRF) studies
Total*
AML 10AML 11AML 12AMLTherapy AML
Total, no. (%) 30 321 207 343 66 927 
Sex, no. (%) 
    Male 16 (53.3) 182 (56.7) 120 (58.0) 188 (54.8) 28 (42.4) 512 (55.2) 
    Female 14 (46.7) 139 (43.3) 87 (42.0) 155 (45.2) 38 (57.6) 415 (44.8) 
Age 
    Mean, y (standard deviation) 41.4 (11.6) 66.8 (5.5) 41.0 (12.1) 47.3 (14.5) 55.1 (13.1) 52.4 (15.6) 
    16 to 39 y, no. (%) 9 (30.0) 88 (42.5) 108 (31.5) 11 (16.7) 213 (23.0) 
    40 to 59 y, no. (%) 21 (70.0) 36 (11.2) 117 (56.5) 150 (43.7) 27 (40.9) 338 (36.5) 
    60 y or older, no. (%) 285 (88.8) 2 (1.0) 85 (24.8) 28 (42.4) 376 (40.6) 
Cytogenetic abnormalities, no. (%) 
    Normal 140 (26.9) 73 (23.2) 146 (30.4) 20 (16.4) 363 (25.1) 
    Monosomy 
        −5 3 (4.0) 20 (3.9) 10 (3.2) 7 (1.5) 4 (3.3) 42 (2.9) 
        −7 9 (11.8) 35 (6.7) 12 (3.8) 15 (3.1) 12 (9.8) 78 (5.4) 
    Trisomy 
        +8 3 (4.0) 36 (6.9) 17 (5.4) 38 (7.9) 10 (8.2) 100 (6.9) 
        +21 2 (2.6) 6 (1.2) 5 (1.6) 9 (1.9) 1 (0.8) 22 (1.5) 
        +22 1 (1.3) 4 (0.8) 4 (1.3) 3 (0.6) 1 (0.8) 13 (0.9) 
    Translocation 
        t(15;17) 1 (1.3) 11 (2.1) 33 (10.5) 42 (8.3) 8 (6.6) 90 (6.2) 
        t(8;21) 1 (1.3) 6 (1.2) 16 (5.1) 24 (5.0) 47 (3.3) 
    Deletion 
        del(5q) 10 (13.2) 39 (7.5) 11 (3.5) 7 (1.5) 4 (3.3) 69 (4.8) 
        del(7q) 6 (7.9) 17 (3.3) 12 (3.8) 15 (3.1) 4 (3.3) 47 (3.3) 
        del(9q) 1 (1.3) 8 (1.5) 7 (2.2) 6 (1.3) 1 (0.8) 22 (1.5) 
    Other 
        3q 10 (1.9) 11 (3.5) 9 (1.9) 5 (4.1) 39 (2.7) 
        11q23 7 (9.2) 8 (1.5) 9 (2.9) 14 (2.9) 8 (6.6) 41 (2.8) 
        Inversion(16) 1 (1.3) 4 (0.8) 7 (2.2) 14 (2.9) 1 (0.8) 26 (1.8) 
        Complex 8 (10.5) 49 (9.4) 25 (7.9) 24 (5.0) 12 (9.8) 112 (7.8) 
        Any other abnormality 18 (23.7) 126 (24.3) 63 (20.0) 113 (23.5) 31 (25.4) 333 (23.0) 
*

There were 23 subjects in the LRF AML study and 7 therapy-AML subjects who were also MRC trial participants; 10 therapy-AML subjects were also in the LRF AML study.

These groups are not mutually exclusive.

Complex indicates 5 or more unrelated abnormalities.

DNA was extracted from whole frozen blood or white cell pellets using proteinase K digestion and phenol/chloroform extraction, or from archived bone marrow smears using the QIAamp DNA mini extraction kit according to the manufacturer's instructions (Qiagen, Hilden, Germany).

Single nucleotide polymorphism genotyping

Leukemia cases were genotyped using polymerase chain reaction/restriction fragment-length polymorphism assay, as previously described.1  Direct sequencing was used to genotype 4% of randomly selected samples; genotyping concordance for different techniques was 100%.

Statistical analysis

Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using unconditional logistic regression9  routinely adjusting for age and sex. XPD genotype was analyzed either as a trichotomous (lys/lys, lys/gln, gln/gln) or dichotomous (lys/lys, lys/gln + gln/gln) variable. All analyses were performed using Stata 9.1 1999 (Stata, College Station, TX). Cases were stratified according to the presence of defined cytogenetic abnormalities, irrespective of the presence of other abnormalities (some groups are therefore not mutually exclusive), and ORs and 95% CIs were calculated using AML cases with a normal karyotype as the reference population.

When grouped according to the presence of specific cytogenetic lesions, those cases without any apparent abnormality (normal karyotype) formed the largest group. The XPD codon 751 polymorphism distribution in this group (n = 363; lys/lys 38.3%, lys/gln 47.1%, gln/gln 14.6%) was not significantly different from United Kingdom cancer-free individuals reported previously (n = 696; lys/lys 42.1%, lys/gln 43.0%, gln/gln 15.0%).1  The normal karyotype case subgroup was used as the reference population in all subsequent analysis.

We can postulate that structurally similar lesions, irrespective of their location in the genome, might have arisen via the same mechanism. As such, for the purposes of an initial analysis we grouped cases according to the presence of structurally similar, commonly occurring cytogenetic aberrations. XPD codon 751 status was not significantly associated with risk of developing AML defined by the presence of a trisomy (+8, +21, +22; n = 122), a monosomy (−5, −7; n = 100), a translocation (t(15;17), t(8;21); n = 137), or a complex karyotype (defined as 5 or more unrelated abnormalities; n = 112; Table 2), but was significantly associated with risk of developing AML with a deletion (del(5q), del(7q), del(9q); n = 128) when compared with the normal karyotype group (OR for lys/gln + gln/gln vs lys/lys 1.65; 95% CI 1.06-2.58; Table 2; P = .03). When stratified by the site of deletion, carrier status for the XPD codon 751 glutamine-encoding variant (lys/gln + gln/gln) was independently associated with risk of del(5q)-positive AML (OR for lys/gln + gln/gln vs lys/lys 2.09; 95% CI 1.14-3.81; P = .02) and del(7q)-positive AML (OR for lys/gln + gln/gln vs lys/lys 2.27; 95% CI 1.09-4.71; P = .03), but was not associated with risk of del(9q)-positive AML (Table 2). One hundred seven patients had a karyotype that included a 5q deletion and/or a 7q deletion, risk for which was strongly associated with carrier status for the XPD codon 751 glutamine-encoding variant (OR for lys/gln + gln/gln vs lys/lys 1.93; 95% CI 1.18-3.16; P = .009; data not shown). Of these, 9 patients had a karyotype that included a 5q deletion and a 7q deletion, and all of these were carriers of the glutamine variant (5 heterozygotes and 4 homozygotes for the glutamine-encoding allele).

Table 2

XPD codon 751 polymorphism status by cytogenetic abnormality

No. totalGenotype
Lys/Lys
Lys/Gln
Gln/Gln
Lys/Gln+Gln/Gln
No. (%)OR (CI)No. (%)OR (CI)No. (%)OR (CI)No. (%)OR (CI)
Monosomy          
    Total XPD codon 751 100 34 (34.0) 51 (51.0) 1.20 (0.73-1.96) 15 (15.0) 1.15 (0.58-2.29) 66 (66.0) 1.19 (0.74-1.89) 
    −5 42 15 (35.7) 21 (50.0) 1.11 (0.55-2.24) 6 (14.3) 1.05 (0.39-2.86) 27 (64.3) 1.10 (0.56-2.14) 
    −7 78 28 (35.9) 39 (50.0) 1.11 (0.65-1.90) 11 (14.1) 1.04 (0.48-2.25) 50 (64.1) 1.10 (0.66-1.83) 
Trisomy          
    Total XPD codon 751 122 46 (37.7) 53 (43.4) 0.94 (0.59-1.48) 23 (18.9) 1.26 (0.69-2.29) 76 (62.3) 1.01 (0.66-1.55) 
    +8 100 36 (36.0) 44 (44.0) 0.99 (0.61-1.63) 20 (20.0) 1.40 (0.74-2.65) 64 (64.0) 1.09 (0.69-1.74) 
    +21 22 8 (36.4) 12 (54.6) 1.23 (0.49-3.12) 2 (9.1) 0.64 (0.13-3.11) 14 (63.6) 1.09 (0.44-2.67) 
    +22 13 2 (15.4) 8 (61.5) 3.61 (0.74-17.58) 3 (23.1) 3.89 (0.63-24.17) 11 (84.6) 3.68 (0.79-17.10) 
Translocation          
    Total XPD codon 751 137 57 (41.6) 61 (44.5) 0.89 (0.56-1.39) 19 (13.9) 0.77 (0.41-1.48) 80 (58.4) 0.86 (0.56-1.31) 
    t(15;17) 90 40 (44.4) 37 (41.1) 0.83 (0.49-1.40) 13 (14.4) 0.80 (0.39-1.68) 50 (55.6) 0.82 (0.50-1.34) 
    t(8;21) 47 17 (36.2) 24 (51.1) 1.22 (0.61-2.43) 6 (12.8) 0.84 (0.30-2.36) 30 (68.8) 1.12 (0.58-2.17) 
Deletion          
    Total XPD codon 751 128 35 (27.3) 69 (53.9) 1.60 (1.01-2.54)* 24 (18.8) 1.85 (1.00-2.54)* 93 (72.7) 1.65 (1.06-2.58)† 
    del(5q) 69 16 (23.2) 36 (52.2) 1.83 (0.97-3.45) 17 (24.6) 2.98 (1.39-6.39) 53 (76.8) 2.09 (1.14-3.81)§ 
    del(7q) 47 10 (21.3) 28 (59.6) 2.23 (1.04-4.76) 9 (19.2) 2.39 (0.92-6.24) 37 (78.7) 2.27 (1.09-4.71) 
    del(9q) 22 9 (40.9) 11 (50.0) 1.00 (0.40-2.48) 2 (9.1) 0.59 (0.12-2.82) 13 (59.1) 0.90 (0.37-2.17) 
Other cytogenetic abnormality          
    Normal karyotype 363 139 (38.3) Reference 171 (47.1) Reference 53 (14.6) Reference 224 (61.7) Reference 
    3q 39 11 (28.2) 21 (53.8) 1.60 (0.74-3.47) 7 (18.0) 1.66 (0.61-4.55) 28 (71.8) 1.62 (0.77-3.38) 
    11q23 41 19 (46.3) 15 (36.6) 0.67 (0.32-1.38) 7 (17.1) 0.94 (0.37-2.40) 22 (53.7) 0.74 (0.38-1.42) 
    Inv(16) 26 14 (53.9) 10 (38.5) 0.62 (0.26-1.45) 2 (7.7) 0.36 (0.08-1.66) 12 (46.2) 0.55 (0.25-1.24) 
    Complex 112 36 (32.1) 57 (50.9) 1.27 (0.79-2.04) 19 (17.0) 1.41 (0.74-2.68) 76 (67.9) 1.30 (0.83-2.04) 
    Any other 333 115 (34.5) 164 (49.3) 1.16 (0.83-1.60) 54 (16.2) 1.22 (0.78-1.92) 218 (65.5) 1.17 (0.86-1.60) 
No. totalGenotype
Lys/Lys
Lys/Gln
Gln/Gln
Lys/Gln+Gln/Gln
No. (%)OR (CI)No. (%)OR (CI)No. (%)OR (CI)No. (%)OR (CI)
Monosomy          
    Total XPD codon 751 100 34 (34.0) 51 (51.0) 1.20 (0.73-1.96) 15 (15.0) 1.15 (0.58-2.29) 66 (66.0) 1.19 (0.74-1.89) 
    −5 42 15 (35.7) 21 (50.0) 1.11 (0.55-2.24) 6 (14.3) 1.05 (0.39-2.86) 27 (64.3) 1.10 (0.56-2.14) 
    −7 78 28 (35.9) 39 (50.0) 1.11 (0.65-1.90) 11 (14.1) 1.04 (0.48-2.25) 50 (64.1) 1.10 (0.66-1.83) 
Trisomy          
    Total XPD codon 751 122 46 (37.7) 53 (43.4) 0.94 (0.59-1.48) 23 (18.9) 1.26 (0.69-2.29) 76 (62.3) 1.01 (0.66-1.55) 
    +8 100 36 (36.0) 44 (44.0) 0.99 (0.61-1.63) 20 (20.0) 1.40 (0.74-2.65) 64 (64.0) 1.09 (0.69-1.74) 
    +21 22 8 (36.4) 12 (54.6) 1.23 (0.49-3.12) 2 (9.1) 0.64 (0.13-3.11) 14 (63.6) 1.09 (0.44-2.67) 
    +22 13 2 (15.4) 8 (61.5) 3.61 (0.74-17.58) 3 (23.1) 3.89 (0.63-24.17) 11 (84.6) 3.68 (0.79-17.10) 
Translocation          
    Total XPD codon 751 137 57 (41.6) 61 (44.5) 0.89 (0.56-1.39) 19 (13.9) 0.77 (0.41-1.48) 80 (58.4) 0.86 (0.56-1.31) 
    t(15;17) 90 40 (44.4) 37 (41.1) 0.83 (0.49-1.40) 13 (14.4) 0.80 (0.39-1.68) 50 (55.6) 0.82 (0.50-1.34) 
    t(8;21) 47 17 (36.2) 24 (51.1) 1.22 (0.61-2.43) 6 (12.8) 0.84 (0.30-2.36) 30 (68.8) 1.12 (0.58-2.17) 
Deletion          
    Total XPD codon 751 128 35 (27.3) 69 (53.9) 1.60 (1.01-2.54)* 24 (18.8) 1.85 (1.00-2.54)* 93 (72.7) 1.65 (1.06-2.58)† 
    del(5q) 69 16 (23.2) 36 (52.2) 1.83 (0.97-3.45) 17 (24.6) 2.98 (1.39-6.39) 53 (76.8) 2.09 (1.14-3.81)§ 
    del(7q) 47 10 (21.3) 28 (59.6) 2.23 (1.04-4.76) 9 (19.2) 2.39 (0.92-6.24) 37 (78.7) 2.27 (1.09-4.71) 
    del(9q) 22 9 (40.9) 11 (50.0) 1.00 (0.40-2.48) 2 (9.1) 0.59 (0.12-2.82) 13 (59.1) 0.90 (0.37-2.17) 
Other cytogenetic abnormality          
    Normal karyotype 363 139 (38.3) Reference 171 (47.1) Reference 53 (14.6) Reference 224 (61.7) Reference 
    3q 39 11 (28.2) 21 (53.8) 1.60 (0.74-3.47) 7 (18.0) 1.66 (0.61-4.55) 28 (71.8) 1.62 (0.77-3.38) 
    11q23 41 19 (46.3) 15 (36.6) 0.67 (0.32-1.38) 7 (17.1) 0.94 (0.37-2.40) 22 (53.7) 0.74 (0.38-1.42) 
    Inv(16) 26 14 (53.9) 10 (38.5) 0.62 (0.26-1.45) 2 (7.7) 0.36 (0.08-1.66) 12 (46.2) 0.55 (0.25-1.24) 
    Complex 112 36 (32.1) 57 (50.9) 1.27 (0.79-2.04) 19 (17.0) 1.41 (0.74-2.68) 76 (67.9) 1.30 (0.83-2.04) 
    Any other 333 115 (34.5) 164 (49.3) 1.16 (0.83-1.60) 54 (16.2) 1.22 (0.78-1.92) 218 (65.5) 1.17 (0.86-1.60) 

A case/case analysis was conducted using subjects with a normal karyotype as the reference group for all comparisons (Lys/Lys, n = 139, 38.3%; Lys/Gln, n = 171, 47.1%; Gln/Gln, n = 53, 14.6%). Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression adjusting for age and sex.

*

P = .05.

P = .03.

P = .005.

§

P = .02.

P = .04.

The association between del(5q)-positive, del(7q)-positive AML and XPD codon 751 status remained significant when the United Kingdom cancer-free control series1  (n = 696) was used as the reference population (del(5q) OR for lys/gln + gln/gln vs lys/lys 2.57; 95% CI 1.42-4.65; P = .002; del(7q) OR for lys/gln + gln/gln vs lys/lys 2.77; 95% CI 1.35-5.69; P = .006). It will of course be important to replicate this study in a second independent series of AML cases with 5q and/or 7q deletions such that we can be confident the association reported is not a false positive.

These data suggest that the XPD locus, located on chromosome 19q13, carries a low penetrance susceptibility allele for AML with somatically acquired long-arm deletions of chromosomes 5 and/or 7. Although rare, a putative susceptibility locus for familial AML with chromosome 5 and/or 7 deletions has been localized to 16q22.10,11  Efforts to identify the responsible locus have proven difficult, although one hypothesis suggests that polymorphic NAD(P)H:quinone oxido-reductase 1, encoded by a locus at 16q22, may affect risk of 5q- and/or 7q-deleted AML by modifying host response to leukemogens, including benzene12  and chemotherapeutic alkylating agents.13  AML that develops after occupational exposure to benzene frequently carries somatic aberrations involving loss of all or part of chromosomes 5 and/or 7, and benzene metabolites have been shown to induce these deletions in cultured cells.14-16  These observations are particularly relevant to our findings because human cells deficient in NER, of which XPD is one component, are sensitive to the mutagenic effects of the benzene metabolite p-benzoquinone in comparison with NER-proficient cells,17  implicating NER in the repair of benzene-induced DNA damage. These observations suggest one plausible biologic mechanism by which polymorphic XPD might predispose to the development of AML with long-arm chromosome 5 and/or 7 deletions.

A second model predicts a role for polymorphic XPD in modulating p53-mediated cell death signaling. XPD is a component of the p53-mediated apoptosis pathway, and the 2 proteins interact directly via the carboxy terminus of XPD, which includes the polymorphic codon 751 residue.18  Consistent with a role for XPD in mediating cell death, fibroblasts with inactivating XPD mutations have attenuated p53-mediated apoptosis.19,20  Given a functional interaction between XPD and p53 it is noteworthy that somatic alterations involving p53 (chromosome 17 monosomy, 17p deletions, and point mutations) are relatively rare in AML per se, but they occur with high frequency in AML with chromosomal losses of 5 and/or 7, and particularly so when found in the context of therapy-related AML after alkylating chemotherapy.21-23  Indeed, there is now considerable evidence to suggest that chromosome 5 and 7 alterations cooperate with p53 alterations to promote myeloid neoplasia. Given this, we can speculate that in a background of chromosome 5 and/or 7 long-arm deletions polymorphisms in XPD may directly impact the ability to signal cell death via a p53-dependent pathway, or that XPD polymorphic variants may predispose to the acquisition of p53 mutations, as has been suggested for lung and bladder cancer.24,25  An inability to signal cell death is predicted to result in the persistence of preleukemic clones and increase the risk of malignant transformation. Consistent with this model, the XPD codon 751 glutamine-encoding allele is significantly associated with an increased risk of developing therapy-related AML, as we have previously reported.1 

In summary, we have identified a polymorphic variant in the XPD DNA repair gene that associates specifically with risk of developing 5q- and/or 7q-deleted AML, supporting the hypothesis that AML subgroups defined by karyotype have independent etiologies and unique risk factors. The identification of common risk factors for independent cytogenetic aberrations might explain why some lesions are seen together more frequently that would otherwise be expected.

Contribution: A.G.S. performed research and analyzed the data; L.J.W. performed research and managed the case series; J.M.A. conceived the hypothesis, performed research, and wrote the paper; all authors commented on and approved the final manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: James M. Allan, Epidemiology and Genetics Unit, Department of Biology, University of York, Heslington, York YO10 5YW, United Kingdom; e-mail: jim.allan@egu.york.ac.uk.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

We are grateful to staff at the Leukaemia Research Fund Epidemiology and Genetics Unit (University of York), and the Medical Research Council Adult Acute Leukaemia Working Party for supporting this work. We acknowledge the support of the Medical Research Council DNA and RNA bank, University College London Hospital, a facility funded in part by the Leukaemia Research Fund, the Medical Research Council, and the Kay Kendall Leukaemia Fund. This work was supported by the Leukaemia Research Fund of the United Kingdom. The Epidemiology and Genetics Unit is a member of the Haematology Research Network for Yorkshire and Humber.

1
Allan JM, Smith AG, Wheatley K, et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy.
Blood
2004
;
104
:
3872
–3877.
2
Kane EV, Roman E, Cartwright R, Parker J, Morgan G. Tobacco and the risk of acute leukaemia in adults.
Br J Cancer
1999
;
81
:
1228
–1233.
3
Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia: results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council.
Blood
1997
;
89
:
2311
–2318.
4
Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1 612 patients entered into the MRC AML 10 trial The Medical Research Council Adult and Children's Leukaemia Working Parties.
Blood
1998
;
92
:
2322
–2333.
5
Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
Blood
2001
;
98
:
1312
–1320.
6
Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.
Blood
2005
;
106
:
3658
–3665.
7
Allan JM, Wild CP, Rollinson S, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia.
Proc Natl Acad Sci U S A
2001
;
98
:
11592
–11597.
8
Worrillow LJ, Travis LB, Smith AG, et al. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents.
Clin Cancer Res
2003
;
9
:
3012
–3020.
9
Breslow NE and Day NE. Classical methods of analysis of matched data.
Statistical Methods in Cancer Research: The Analysis of Case-Control Studies
1980
;Lyon, France International Agency for Research in Cancer
1
: pp.
162
–189.
10
Horwitz M, Benson KF, Li FQ, et al. Genetic heterogeneity in familial acute myelogenous leukemia: evidence for a second locus at chromosome 16q21–23.2.
Am J Hum Genet
1997
;
61
:
873
–881.
11
Gao Q, Horwitz M, Roulston D, et al. Susceptibility gene for familial acute myeloid leukemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q.
Genes Chromosomes Cancer
2000
;
28
:
164
–172.
12
Escher R, Jones A, Hagos F, et al. Chromosome band 16q22-linked familial AML: exclusion of candidate genes, and possible disease risk modification by NQO1 polymorphisms.
Genes Chromosomes Cancer
2004
;
41
:
278
–282.
13
Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609C—T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia.
Blood
1999
;
94
:
803
–807.
14
Stillman WS, Varella-Garcia M, Irons RD. The benzene metabolites hydroquinone and catechol act in synergy to induce dose-dependent hypoploidy and -5q31 in a human cell line.
Leuk Lymphoma
1999
;
35
:
269
–281.
15
Stillman WS, Varella-Garcia M, Irons RD. The benzene metabolite, hydroquinone, selectively induces 5q31- and -7 in human CD34+.
Exp Hematol
2000
;
28
:
169
–176.
16
Zhang L, Wang Y, Shang N, Smith MT. Benzene metabolites induce the loss and long arm deletion of chromosomes 5 and 7 in human lymphocytes.
Leuk Res
1998
;
22
:
105
–113.
17
Gaskell M, McLuckie KI, Farmer PB. Comparison of the repair of DNA damage induced by the benzene metabolites hydroquinone and p-benzoquinone: a role for hydroquinone in benzene genotoxicity.
Carcinogenesis
2005
;
26
:
673
–680.
18
Seker H, Butkiewicz D, Bowman ED, et al. Functional significance of XPD polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype.
Cancer Res
2001
;
61
:
7430
–7434.
19
Robles AI, Wang XW, Harris CC. Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of TFIIH in p53-mediated apoptotic cell death.
Oncogene
1999
;
18
:
4681
–4688.
20
Wang XW, Vermeulen W, Coursen JD, et al. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway.
Genes Dev
1996
;
10
:
1219
–1232.
21
Soenen V, Preudhomme C, Roumier C, et al. 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome: analysis of breakpoints and deleted segments by fluorescence in situ.
Blood
1998
;
91
:
1008
–1015.
22
Horiike S, Misawa S, Kaneko H, et al. Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of nos 5 and/or 7 and its possible relationship to replication error phenotype.
Leukemia
1999
;
13
:
1235
–1242.
23
Castro PD, Liang JC, Nagarajan L. Deletions of chromosome 5q13 3 and 17p loci cooperate in myeloid neoplasms.
Blood
2000
;
95
:
2138
–2143.
24
Stern MC, Conway K, Li Y, Mistry K, Taylor JA. DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer.
Mol Carcinog
2006
;
45
:
715
–719.
25
Mechanic LE, Marrogi AJ, Welsh JA, et al. Polymorphisms in XPD and TP53 and mutation in human lung cancer.
Carcinogenesis
2005
;
26
:
597
–604.
Sign in via your Institution